Why was lesinurad discontinued?

Why was lesinurad discontinued?

Zurampic (lesinurad) is a URAT1 inhibitor indicated for the combination treatment of hyperuricemia associated with gout. On April 15, 2019, the FDA announced the discontinuation of Zurampic (lesinurad). The discontinuation was due to business reasons, and not due to any safety, efficacy or quality issues.

How much does lesinurad cost?

Price. A one-month supply of lesinurad costs approximately $394. It is significantly more expensive than probenecid, which costs about $34 for a 30-day supply. In addition, a one-month supply of allopurinol costs about $10.

What is lesinurad used for?

Lesinurad is used in combination with a xanthine oxidase inhibitor to treat hyperuricemia (high levels of uric acid) in people with gout (sudden attacks of redness, swelling, pain, and heat in one or more joints) whose disease is not controlled with their current medication.

Is lesinurad still available?

On April 15, 2019, the FDA announced the discontinuation of Ironwood Pharmaceuticals’ Duzallo (lesinurad/allopurinol) and Zurampic (lesinurad). — The discontinuation was due to business reasons and is not due to any safety, efficacy or quality issues. — These products were discontinued as of February 1, 2019.

Is lesinurad available in USA?

( NASDAQ : IRWD) today announced that ZURAMPIC® (lesinurad) is now available in pharmacies throughout the United States .

What is the mechanism of action of lesinurad?

7.7Mechanism of Action Lesinurad inhibits the activity of uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4). URAT1 is a major transporter enzyme responsible for reuptake of uric acid from the renal tubules; inhibition of URAT1 function thereby increases excretion of uric acid.

Is lesinurad available in the US?

What can I use instead of allopurinol?

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.

Why can’t Chinese take allopurinol?

Stern noted that genetic epidemiology can play a strong roll in allopurinol hypersensitivity, as the HLA-B*5801 haplotype, which is prevalent in Han Chinese individuals, is a major risk factor.

What company originally developed krystexxa?

Originally developed by Savient Pharmaceuticals, Krystexxa was taken on by Horizon Pharma in 2015. Since then, the company has seen a 40-50% growth in patients over the last year. Gout can be a debilitating disease characterized by recurrent attacks of tender, hot and swollen joints.